EUVIMEDEUVIMED entdecken
Crossref

Liver viscosity: pathological significance and interest for the assessment of MASLD severity in clinical practice

Anita Paisant, Marine Roux, Paul Calame, Arthur Lecharpentier, Thierry Thevenot, Christophe Aubé, Jérôme Boursier

European Radiology · 2025

DOI: 10.1007/s00330-025-12142-7 ↗

Kurz gefasst

Fachartikel in der Zeitschrift European Radiology, 2025. Verfasst von Anita Paisant und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Radiology, University Hospital of Angers, Angers, France. Hauptthemen laut MEDLINE: Elasticity Imaging Techniques, Liver, Fatty Liver. Die Arbeit nennt 27 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

OBJECTIVES: The non-invasive diagnosis of metabolic dysfunction-associated steatohepatitis (MASH) is a critical unmet need. Liver viscosity is a new ultrasound measurement based on 2D-Shear Wave Elastography (2D-SWE). We aimed to characterize the association between liver viscosity and histologic component, and to determine whether this new parameter can improve the non-invasive diagnosis of MASH. MATERIALS AND METHODS: Two hundred seventy-five patients undergoing liver biopsy for suspected MASLD were included and had 2D-SWE with liver viscosity measurements. Patients were enrolled in Angers University Hospital (derivation set, n = 183) and Besançon University Hospital (validation set, n = 92) centers. MASH was defined on liver biopsy as the presence of steatosis with lobular inflammation and ballooning. RESULTS: Independent predictors of MASH in the derivation set (BMI, gender, liver viscosity) were combined into the MASH score. The AUROC of the MASH score was 0.85 [95% CI: 0.79-0.92] in the derivation set and 0.82 [95% CI: 0.73-0.92] in the validation set. The rule-out (≤ 0.578) and rule-in (≥ 0.863) thresholds determined in the derivation set provided, respectively, 84% sensitivity and 96% specificity in the validation set. The AUROC of 2D-SWE for significant fibrosis F ≥ 2 was 0.82 [95% CI: 0.77-0.88]. The MASH score was combined with 2D-SWE to diagnose fibrotic MASH, which is the indication for pharmacological therapy. The AUROC of the combination was 0.81 [95% CI: 0.74-0.87] in the derivation set and 0.78 [95% CI: 0.69-0.87] in the validation set. CONCLUSION: The ultrasound-based MASH score accurately diagnoses MASH. Combined with 2D-SWE available in the same device, it accurately identifies MASLD patients who require pharmacological therapy. KEY POINTS: Question The transition from MASLD to MASH is critical, yet no simple non-invasive diagnostic method currently exists for accurately identifying MASH patients. Findings Liver viscosity measured by 2D-SWE, combined with BMI and gender, provides a score (MASH score) that accurately diagnoses MASH. Clinical relevance This ultrasound-based MASH score offers a practical and widely accessible tool to identify patients with MASH or fibrotic MASH requiring follow-up and treatment, improving management of MASH.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Elasticity Imaging TechniquesLiverFatty LiverHumansMaleFemaleViscosityMiddle AgedSeverity of Illness IndexAdultBiopsySensitivity and SpecificityAged

Stichwörter der Autor:innen

DiagnosisElasticity Imaging TechniquesLiver DiseaseViscosity

Autor:innen und Institutionen

  • Department of Radiology, University Hospital of Angers, Angers, France.
  • Laboratoire HIFIH UPRES 3859, SFR ICAT 4208, Angers University, Angers, France.
  • Department of Radiology, University of Bourgogne Franche-Comté, CHRU Besançon, Besançon, France.
  • EA 4662 Nanomedicine Lab, Imagery and Therapeutics, University of Franche-Comté, Besançon, France.
  • Department of hepatology, University Hospital of Besançon, CHU de Besançon, Besançon, France.
  • Department of Radiology, University Hospital of Angers, Angers, France. ChAube@chu-angers.fr.

Zitieren

APA

Paisant, A., Roux, M., Calame, P., Lecharpentier, A., Thevenot, T., Aubé, C., & Boursier, J. (2025). Liver viscosity: pathological significance and interest for the assessment of MASLD severity in clinical practice. European Radiology. https://doi.org/10.1007/s00330-025-12142-7

Vancouver

Paisant A, Roux M, Calame P, Lecharpentier A, Thevenot T, Aubé C, et al. Liver viscosity: pathological significance and interest for the assessment of MASLD severity in clinical practice. European Radiology. 2025. doi:10.1007/s00330-025-12142-7

BibTeX
@article{Paisant2025,
  author = {Paisant, Anita and Roux, Marine and Calame, Paul and Lecharpentier, Arthur and Thevenot, Thierry and Aubé, Christophe and Boursier, Jérôme},
  title = {Liver viscosity: pathological significance and interest for the assessment of MASLD severity in clinical practice},
  journal = {European Radiology},
  year = {2025},
  doi = {10.1007/s00330-025-12142-7}
}
Kostenlos starten →